<DOC>
	<DOCNO>NCT01953809</DOCNO>
	<brief_summary>This study conduct confirm GSK1322322 negative impact hormone level contraceptive efficacy co-administered frequently prescribe oral contraceptive thereby facilitate use GSK1322322 woman child-bearing potential receive oral contraceptive ( OC ) pre-infection . This study design investigate steady-state plasma ethinyl estradiol ( EE ) norethindrone ( NE ) pharmacokinetic ( PK ) follow administration Ortho-Novum ( EE/NE ) 1 tablet every 24 hour ( q24h ) feed without GSK1322322 1500 milligram ( mg ) q12h feed . Each subject participate study approximately 12 week : 30 day screen period , 4-week run-in period , three 7 day treatment period , 3-5 day follow-up period . The study plan enroll approximately 24 subject ( 18 active/6 placebo ) .</brief_summary>
	<brief_title>A Pharmacokinetics , Pharmacodynamics , Safety Study Oral Contraceptive Containing Norethindrone Ethinyl Estradiol When Co-administered With GSK1322322 Healthy Adult Women</brief_title>
	<detailed_description>Please note Ortho-Novum register trademark Ortho Pharmaceutical Corporation .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test , cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator feel find unlikely introduce additional risk factor interfere study procedure . Non smoke female ( childbearing age ) , 18 45 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy without oophorectomy ( least one function ovary require ) child bear age presence nondrug elute intra uterine device ( IUD ) i.e . copper . NOTE : The IUD placement need confirm obstetriciangynecologist . Subjects must willing use EE/NE combination one follow appropriate contraceptive method least 14 day prior first dose study drug completion followup visit Complete abstinence intercourse least 14 day prior first dose IP , throughout study , subsequent post study monitoring ; A barrier method plus spermicide ( e.g. , condom diaphragm spermicidal foam/gel/cream/ suppository least 14 day prior first dose IP throughout study , subsequent post study monitor Sterilization ( vasectomy ) male partner prior commencement female subject 's last normal menstrual period prior IP administration male partner sole partner female subject Body weight &gt; =50 kilogram ( kg ) ( 110 pound [ lbs ] ) &lt; 114kg ( &lt; 250 lb ) body mass index within range 19 32 kg/meter^2 ( inclusive ) . Alanine aminotransferase , alkaline phosphatase bilirubin &lt; =1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) screening checkin ( repeat allow checkin ) . QT interval correct heart rate Bazett 's formula ( QTcB ) &lt; 450 millisecond ( msec ) screening checkin . Capable give write informed consent , include compliance requirement restriction list consent form Pregnant female determine positive human chorionic gonadotropin ( hCG ) test screen prior dosing . History condition would contraindicate OrthoNovum administration ( include hypertension , stroke , ischemic heart disease , venous thromboembolism family history thromboembolism , know factor V Leiden mutation gene mutation associate increase risk thromboembolism , migraine headache , carcinoma breast , liver endometrium , gallbladder disease , history undiagnosed abnormal uterine bleeding , etc . Females condition concurrent medication could adversely affect hormone level ( e.g . oophorectomy ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Endocrine system : untreated unstable thyroid disorder and/or diabetes mellitus ( I II ) . Treatment condition must stable least 4 week prior first dose study drug . Have suffer urinary tract , bladder , vaginal infection within 4 week prior first dose study drug , urinalysis result Screening consistent urinary tract infection . Subjects diagnosed infection Screening treat appropriately may rescreened 4 week . Fasting triglyceride &gt; 300 mg/deciliter ( dL ) Screening . A positive prestudy Hepatitis B surface antigen , positive Hepatitis C antibody , positive test human immuno virus ( HIV ) antibody result within 3 month screen . A positive prestudy drug/alcohol screen . History regular alcohol consumption within 6 month study define An average weekly intake &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Concurrentmedications alter gastrointestinal motility result diarrhea bind study drug ( example erythromycin , antacid , prokinetic agent , cholestyramine ) . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety due potential drug interaction . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoking regular use tobacco nicotinecontaining product within 4 week prior screen . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice [ and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ] 7 day prior first dose study medication . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : Female subject Heart rate &lt; 50 &gt; 100 beat per minute ( bpm ) , PR interval &lt; 120 &gt; 220 msec , QRS duration &lt; 70 &gt; 120 msec , QTcB &gt; =450 msec ( Note : The waveform must enable QT interval clearly define ) , Q wave &gt; 30 msec Evidence previous myocardial infarction ( include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right bundle branch block , AV block ( 2nd degree high ) , Wolf Parkinson White ( WPW ) syndrome ) , sinus pause &gt; 3 second , nonsustained sustain ventricular tachycardia ( &gt; =3 consecutive ventricular ectopic beat ) significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>oral</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>GSK1322322</keyword>
	<keyword>antibiotic</keyword>
	<keyword>safety</keyword>
</DOC>